Financial Performance - The company's revenue for Q1 2024 was CNY 262,669,977.50, representing a year-over-year increase of 4.05%[5] - Net profit attributable to shareholders decreased by 29.39% to CNY 26,074,943.00 compared to the same period last year[5] - The basic and diluted earnings per share were both CNY 0.29, reflecting a decline of 29.27% year-over-year[5] - Total operating revenue for Q1 2024 was CNY 262,669,977.50, an increase of 4.87% compared to CNY 252,455,900.29 in Q1 2023[18] - Net profit for Q1 2024 was CNY 26,074,943.00, a decrease of 29.3% from CNY 36,928,240.19 in Q1 2023[19] - Earnings per share for Q1 2024 was CNY 0.29, down from CNY 0.41 in Q1 2023[19] Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,381,919,508.50, a decrease of 1.37% from the end of the previous year[6] - Total assets as of Q1 2024 amounted to CNY 2,381,919,508.50, a slight decrease from CNY 2,415,027,980.82 at the end of the previous period[16] - Total liabilities for Q1 2024 were CNY 336,679,198.66, compared to CNY 325,485,828.49 in the previous period, reflecting an increase of 4.0%[16] - Total non-current assets decreased to CNY 142,171,264.41 from CNY 153,861,833.35, indicating a decline of 7.6%[16] Equity and Shareholder Information - The total equity attributable to shareholders decreased by 2.12% to CNY 2,045,240,309.84 compared to the end of the previous year[6] - The company’s total equity decreased to CNY 2,045,240,309.84 from CNY 2,089,542,152.33, reflecting a decline of 2.12%[16] - Total number of common shareholders at the end of the reporting period was 4,933[11] - The top 10 shareholders collectively hold 47.03% of the company's shares, with the largest shareholder being Dai Lan, holding 32.6%[12] - The company has a share repurchase account holding 2,129,043 shares, representing 2.34% of total shares[12] - The company is actively managing its shareholder relationships, with no reported related party transactions among other shareholders[12] Cash Flow - The net cash flow from operating activities was CNY 48,167,499.32, with no comparative data available[5] - Cash inflow from operating activities for Q1 2024 was $283.64 million, an increase of 3.0% compared to $274.83 million in Q1 2023[21] - Net cash flow from operating activities for Q1 2024 was $48.17 million, a significant recovery from a net outflow of $21.46 million in Q1 2023[21] - Cash outflow for purchasing goods and services decreased to $162.27 million in Q1 2024 from $238.12 million in Q1 2023, representing a reduction of 31.8%[21] - Cash inflow from investment activities was $1.36 million in Q1 2024, down from $3.47 million in Q1 2023, indicating a decline of 60.8%[22] - Net cash flow from investment activities was -$0.95 million in Q1 2024, an improvement from -$7.00 million in Q1 2023[22] - Cash inflow from financing activities increased significantly to $39.75 million in Q1 2024 from $0.19 million in Q1 2023[22] - Net cash flow from financing activities was -$37.13 million in Q1 2024, worsening from -$3.05 million in Q1 2023[22] - The ending cash and cash equivalents balance for Q1 2024 was $1.27 billion, compared to $1.46 billion at the end of Q1 2023[22] - The company experienced a foreign exchange impact of -$0.92 million on cash and cash equivalents in Q1 2024, compared to -$0.17 million in Q1 2023[22] Expenses and Costs - Research and development expenses totaled CNY 15,420,297.35, accounting for 5.87% of revenue, down 0.53 percentage points from the previous year[6] - The company experienced a decline in net profit primarily due to the growth rate of costs and expenses exceeding that of revenue[9] - Total operating costs for Q1 2024 were CNY 225,411,993.32, up 10.83% from CNY 203,401,460.75 in Q1 2023[18] - The company reported a financial expense of CNY -7,645,483.44 in Q1 2024, compared to CNY -2,676,576.18 in Q1 2023, showing an increase in financial costs[18] Other Information - The company is focused on expanding its market presence and developing new products and technologies[11] - The company reported cash and cash equivalents of approximately ¥1.28 billion, an increase from ¥1.27 billion at the end of 2023[14] - Total current assets amounted to approximately ¥2.24 billion, a slight decrease from ¥2.26 billion in the previous period[14] - Inventory decreased to approximately ¥670.41 million from ¥699.43 million[14] - The company’s deferred income tax assets were CNY 18,841,531.42, slightly up from CNY 18,360,441.47 in the previous period[16] - The company did not adopt new accounting standards for the first quarter of 2024[23]

上海毕得医药科技股份有限公司 年度募集资金存放与使用情况鉴证报告 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-88879999 Fax. 0571-88879000 www.zhcpa.cn 目 录 | 二、上海毕得医药科技股份有限公司关于 2023 年度募集资金 | | | --- | --- | | 一、年度募集资金存放与使用情况鉴证报告 存放与使用情况的专项报告 | 页 次 1-2 3-9 | 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-88879999 Fax. 0571-88879000 www.zhcpa.cn 年 ...

Financial Performance - In 2023, the company achieved a net profit attributable to shareholders of RMB 109,571,788.68, with an undistributed profit of RMB 150,677,721.62 at year-end[6]. - The proposed cash dividend is RMB 9 per 10 shares, resulting in a total cash dividend distribution of RMB 79,878,515, which represents 72.90% of the annual net profit attributable to shareholders[6]. - The company's operating revenue for 2023 reached ¥1,091,858,561.97, representing a 30.94% increase compared to ¥833,831,622.63 in 2022[22]. - The net profit attributable to shareholders decreased by 24.94% to ¥109,571,788.68 from ¥145,970,727.07 in the previous year[22]. - The net cash flow from operating activities was negative at -¥57,387,600.78, a decline of 292.12% compared to ¥29,871,071.18 in 2022[22]. - The company's gross profit margin decreased from 44.38% in 2022 to 40.00% in the reporting period, indicating a continuous decline[86]. - The company reported a total revenue of 8,170 million RMB for the year, with a year-on-year increase of 52.5% from 5,382.86 million RMB[75]. - The company achieved a total revenue of RMB 1,091,858,561.97 in the reporting period, representing a year-on-year growth of 30.94%[90]. Research and Development - The company remains focused on research and development of new products and technologies, although specific details are not provided in the extracted content[12]. - Research and development expenses accounted for 5.79% of operating revenue, an increase of 0.26 percentage points year-on-year[24]. - The company has developed multiple new types of molecular building blocks, optimizing cyclization preparation reactions to expand application ranges[75]. - Total R&D investment for the year reached ¥63,227,409.30, a 37.23% increase from the previous year, with R&D expenses accounting for 5.79% of total revenue[61]. - The company is enhancing its research capabilities in modern organic chemistry and materials science to support new product development[71]. - The company is currently developing KRAS G12C inhibitors with a focus on boronic acid building blocks, aiming to enhance synthesis methods and production scalability[72]. - The ongoing research on RAR agonists involves optimizing boronic acid building blocks to improve their properties for client selection[73]. Market Expansion and Strategy - The company plans to enhance its warehouse capabilities in the U.S. with intelligent layout to strengthen its global competitive position[36]. - The company aims to enhance its global presence by establishing regional centers in key new drug research areas and increasing business development efforts in overseas markets[124]. - The company is exploring new strategies for market expansion and product development in the field of advanced organic chemistry[65]. - The company plans to continue expanding its global market presence and enhance customer support capabilities[82]. - The company is focusing on expanding its market presence through innovative drug development and advanced materials technology[66]. - The company plans to build a digital system to enhance data connectivity across various business processes, aiming for high-quality growth in the long term[126]. Corporate Governance and Compliance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[9]. - The company has received a standard unqualified audit report from Zhonghui Certified Public Accountants[5]. - The board of directors and management have confirmed the authenticity, accuracy, and completeness of the annual report[4]. - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective internal control[184]. - The company emphasizes the importance of ESG (Environmental, Social, and Governance) strategies and has integrated them into its overall business strategy[185]. - The company maintains a structured governance framework to protect the rights of shareholders and creditors[200]. Risk Management - The company has outlined various risks and countermeasures in the report, emphasizing the importance of investor awareness regarding investment risks[4]. - The company maintains a focus on risk management in its foreign exchange hedging activities, adhering to principles of legality, prudence, safety, and effectiveness[120]. Employee and Talent Management - The total number of employees in the parent company and major subsidiaries is 846, with 413 in the parent company and 433 in subsidiaries[166]. - The company organized 67 offline training sessions during the reporting period to enhance employee skills and knowledge[169]. - The average salary for R&D personnel decreased to 24.05 million RMB from 25.61 million RMB, reflecting adjustments in compensation strategy[77]. - The company emphasizes the importance of building a talent pipeline and enhancing corporate culture to support high-quality development[124]. Environmental Responsibility - The company invested 2.79 million yuan in environmental protection during the reporting period[186]. - The company is not classified as a key pollutant discharge unit and has complied with environmental impact assessment requirements[187]. - The company has established an environmental management system compliant with ISO14001:2015 standards[194]. - The company focuses on reducing energy consumption and has implemented measures to manage water and electricity usage effectively[195].

上海毕得医药科技股份有限公司 独立董事张萌 2023 年度述职报告 作为上海毕得医药科技股份有限公司（以下简称"公司"）的独立董事，2023 年本人在任职期间严格按照《上市公司独立董事管理办法》、《上海证券交易所 科创板股票上市规则》、《上市公司治理准则》等相关法律、法规，以及《上海 毕得科技股份有限公司公司章程》（以下简称"《公司章程》"）、《上海毕得 科技股份有限公司独立董事制度》等制度规定，在 2023 年度工作中，尽职尽责 地履行独立董事的职责，积极出席相关会议，认真审议董事会各项议案，从公司 整体利益出发，发挥了独立董事应有的作用，维护了公司和全体股东特别是中小 股东的合法权益。现将本人 2023 年度履行独立董事职责的情况汇报如下： 一、独立董事的基本情况 （一）工作履历、专业背景以及兼职情况 公司第一届董事会有三名独立董事，分别是本人，魏炜先生，田伟生先生， 独立董事的选任均符合《公司法》等有关法律法规及公司章程要求。本人基本情 况如下： 张萌，男，中国国籍，无境外永久居留权，1971 年出生，硕士研究生学历， 中国注册会计师（非执业），中国注册税务师。1994 年 9 月至 1997 年 3 ...

上海毕得医药科技股份有限公司 独立董事孟鸿 2023 年度述职报告 作为上海毕得医药科技股份有限公司（以下简称"公司"）的独立董事，2023 年本人在任职期间严格按照《上市公司独立董事管理办法》、《上海证券交易所 科创板股票上市规则》、《上市公司治理准则》等相关法律、法规，以及《上海 毕得科技股份有限公司公司章程》（以下简称"《公司章程》"）、《上海毕得 科技股份有限公司独立董事制度》等制度规定，在 2023 年度工作中，尽职尽责 地履行独立董事的职责，积极出席相关会议，认真审议董事会各项议案，从公司 整体利益出发，发挥了独立董事应有的作用，维护了公司和全体股东特别是中小 股东的合法权益。现将本人 2023 年度履行独立董事职责的情况汇报如下： 一、独立董事的基本情况 （一）工作履历、专业背景以及兼职情况 公司第二届董事会有三名独立董事，分别是本人，刘志常先生，陶永平先生， 独立董事的选任均符合《公司法》等有关法律法规及公司章程要求。本人基本情 况如下： 孟鸿，男，中国国籍，无境外永久居留权，1966 年出生，博士研究生学历。 荣获国家"特聘专家"，广东省珠江人才计划"领军人才"，深圳市"海外高层 次人才 A ...

证券代码：688073 证券简称：毕得医药 公告编号：2024-015 上海毕得医药科技股份有限公司 2023 年度募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性依法承担法律责任。 根据《上市公司监管指引第 2 号——上市公司募集资金管理 和使用的监管要求》《上海证券交易所科创板股票上市规则》以 及《上海证券交易所科创板上市公司自律监管指引第 1 号——规 范运作（2023 年 12 月修订）》的相关规定，上海毕得医药科技股 份有限公司（以下简称"公司"）将 2023 年度募集资金存放与 使用情况报告如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 根据中国证券监督管理委员会《关于同意上海毕得医药科技 股份有限公司首次公开发行股票注册的批复》(证监许可 [2022]1885 号),公司首次向社会公开发行人民币普通股(A 股) 股票 1,622.9100 万股，每股面值 1.00 元，每股发行价 88.00 元。 共计募集资金 1,428,160,800.00 元，扣除不含税承销和保荐费 ...

作为上海毕得医药科技股份有限公司（以下简称"公司"）的独立董事，2023 年本人在任职期间严格按照《上市公司独立董事管理办法》、《上海证券交易所 科创板股票上市规则》、《上市公司治理准则》等相关法律、法规，以及《上海 毕得科技股份有限公司公司章程》（以下简称"《公司章程》"）、《上海毕得 科技股份有限公司独立董事制度》等制度规定，在 2023 年度工作中，尽职尽责 地履行独立董事的职责，积极出席相关会议，认真审议董事会各项议案，从公司 整体利益出发，发挥了独立董事应有的作用，维护了公司和全体股东特别是中小 股东的合法权益。现将本人 2023 年度履行独立董事职责的情况汇报如下： 一、独立董事的基本情况 （一）工作履历、专业背景以及兼职情况 公司第二届董事会有三名独立董事，分别是本人，刘志常先生，孟鸿先生， 独立董事的选任均符合《公司法》等有关法律法规及公司章程要求。本人基本情 况如下： 上海毕得医药科技股份有限公司 独立董事陶永平 2023 年度述职报告 陶永平，男，中国国籍，无境外永久居留权，1963 年出生，现任上海商业 会计学校会计教学部专任教师，高级经济师。1986 年毕业于安徽财经大学会计 与统计专 ...

上海毕得医药科技股份有限公司董事会 关于独立董事独立性自查情况的专项报告 根据《上市公司独立董事管理办法》、《上海证券交易所科创板上市公司自 律监管指引第 1 号——规范运作》等要求，上海毕得医药科技股份有限公司（以 下简称"公司"）董事会，就公司在任独立董事刘志常先生、孟鸿先生、陶永平 先生的独立性情况进行评估并出具如下专项意见： 经核查独立董事刘志常先生、孟鸿先生、陶永平先生及其直系亲属和主要社 会关系人员的任职经历以及独立董事签署的相关自查文件，独立董事刘志常先生、 孟鸿先生、陶永平先生不存在《上市公司独立董事管理办法》第六条不得担任独 立董事的情形，在担任公司独立董事期间，独立董事已严格遵守中国证监会和上 海证券交易所的相关规定，确保有足够的时间和精力勤勉尽责地履行职责，作出 独立判断，不受公司主要股东、实际控制人或其他与公司存在利害关系的单位或 个人的影响。公司独立董事刘志常先生、孟鸿先生、陶永平先生符合《上市公司 独立董事管理办法》《上海证券交易所科创板上市公司自律监管指引第 1 号—— 规范运作》中对独立董事独立性的相关要求。 特此报告。 上海毕得医药科技股份有限公司董事会 2024 年 4 月 ...

证券代码：688073 证券简称：毕得医药 公告编号：2024-013 上海毕得医药科技股份有限公司 第二届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚 假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海毕得医药科技股份有限公司(以下简称"公司")第二届 监事会第六次会议于 2024 年 4 月 25 日在公司会议室召开。本次 会议通知及相关资料已于 2024 年 4 月 15 日送达全体监事。本次 会议由监事会主席蔡媚女士召集并主持，会议应出席监事 3 名， 实际出席监事 3 名，本次会议的召集、召开方式符合相关法律、 行政法规、部门规章、规范性文件和《上海毕得医药科技股份有 限公司章程》的规定，会议决议合法有效。 二、监事会会议审议情况 经与会监事审议表决，形成的会议决议如下： 本议案尚需提交股东大会审议。 3、审议通过了《关于公司 2023 年度利润分配方案的议案》 监事会认为：公司本次利润分配方案，充分考虑了公司日常 运营及长远发展，结合了公司盈利情况、现金流状态和资金需求 等综合因素，同时合理考虑了股东回 ...

关于上海毕得医药科技股份有限公司 非经营性资金占用及其他关联资金往来情况的专项审核说明 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-88879999 Fax. 0571-88879000 www.zhcpa.cn 日 录 | | 页 次 | | --- | --- | | 一、非经营性资金占用及其他关联资金往来情况的专项 | | | 审核说明 | 1-2 | 二、非经营性资金占用及其他关联资金往来情况汇总表 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New City, Hangzhou Tel, 0571-88879999 Fax. 0571-888790.00 www.zhcpa ...